Bio-Path Holdings Inc. is a clinical-stage biotechnology company focused on developing targeted RNAi nanoparticle cancer therapies. Their proprietary liposomal delivery technology and drug discovery platform aim to revolutionize cancer treatment, offering potentially more effective and less toxic alternatives to current therapies. With multiple products in development, Bio-Path is poised to make significant advancements in the field of oncology.
Notification